Meeting
2020 ASCO Virtual Scientific Program
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
Authors
Elizabeth Iannotti Buchbinder
Beth Israel Deaconess Medical Center, Boston, MA
Elizabeth Iannotti Buchbinder , Justine Vanessa Cohen , Rizwan Haq , F. Stephen Hodi , Donald P. Lawrence , Anita Giobbie-Hurder , Deb Knoerzer , Ryan J. Sullivan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03417739
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10036)
DOI
10.1200/JCO.2020.38.15_suppl.10036
Abstract #
10036
Poster Bd #
385
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Clinical trial in progress: Phase II trial of defactinib (VS-6063) combined with VS-6766 (CH5126766) in patients with metastatic uveal melanoma.
First Author: Rino S. Seedor
Poster
2019 ASCO Annual Meeting
Pharmacodynamics of PI3K, MEK, and AKT inhibitors through isoform-specific measurements of MEK, ERK, AKT, and ribosomal protein S6 in needle biopsies.
First Author: William Herrick
Poster
2017 ASCO Annual Meeting
Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor.
First Author: Kimberly Mayumi Komatsubara
Poster
2022 ASCO Annual Meeting
Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis.
First Author: Ceren Durer